BCL6 BTB‐specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque ( Macaca mulatta )
Journal of Medical Primatology · 2020-02 · 49 (1) · 26-33
DOI: 10.1111/jmp.12438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Primatology, 2019-10. Verfasst von Yanhui Cai und 11 weiteren Autor:innen. Beteiligte Einrichtung: HIV-1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, PA, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
The BTB domain of B‐cell lymphoma 6 (BCL6) protein was identified as a therapeutic target for B‐cell lymphoma. This study compared the pharmacokinetics (PK) of the BCL6 BTB inhibitor (FX1) between mice and macaques, as well as evaluating its lymphoid suppressive effect in uninfected macaques with lymphoid hyperplasia. Materials and Methods Eight uninfected adult Indian rhesus macaques ( Macaca mulatta ) were used in the study, four animals carrying lymphoid tissue hyperplasia. Plasma FX1 levels were measured by HPLC‐MS/MS. Lymph node biopsies were used for H&E and immunohistochemistry staining, as well as mononuclear cell isolation for flow cytometry analysis.
Results
Inhibition of the BCL6 BTB domain with FX1 led to a reduction in the frequency of GC, Tfh CD4 + , and Tfh precursor cells, as well as resolving lymphoid hyperplasia, in rhesus macaques.
Conclusions
B‐cell lymphoma 6 inhibition may represent a novel strategy to reduce hyperplastic lymphoid B‐cell follicles and decrease Tfh cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV-1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, PA, USA.
- Division of Comparative Pathology, Tulane National Primate Research Center, Covington, LA, USA.
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA.
- Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
ORCID-Profile: Xiaolei Wang, Luis J Montaner
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NIH HHS
- Philadelphia Foundation
- Center for AIDS Research, University of Washington
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Cai, Y., Watkins, M. A., Xue, F., Ai, Y., Cheng, H., Midkiff, C. C., Wang, X., Alvarez, X., Poli, A. N. R., Salvino, J. M., Veazey, R. S., & Montaner, L. J. (2020). BCL6 BTB‐specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque ( Macaca mulatta ). Journal of Medical Primatology, 49(1), 26-33. https://doi.org/10.1111/jmp.12438
Vancouver
Cai Y, Watkins MA, Xue F, Ai Y, Cheng H, Midkiff CC, et al. BCL6 BTB‐specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque ( Macaca mulatta ). Journal of Medical Primatology. 2020;49(1):26-33. doi:10.1111/jmp.12438
BibTeX
@article{Cai2020,
author = {Cai, Yanhui and Watkins, Meagan A and Xue, Fengtian and Ai, Yong and Cheng, Huiming and Midkiff, Cecily C and Wang, Xiaolei and Alvarez, Xavier and Poli, Adi Narayana Reddy and Salvino, Joseph M and Veazey, Ronald S and Montaner, Luis J},
title = {BCL6 BTB‐specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque ( Macaca mulatta )},
journal = {Journal of Medical Primatology},
year = {2020},
volume = {49},
number = {1},
pages = {26--33},
doi = {10.1111/jmp.12438}
}
EUVIMED